IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
Ann‐Lii Cheng(National Taiwan University Hospital), S. Qin, Masafumi Ikeda(National Cancer Center Hospital East), Peter R. Galle(Johannes Gutenberg University Mainz), Michel Ducreux(Institut Gustave Roussy), Andrew X. Zhu(Massachusetts General Hospital), T.-Y. Kim(Seoul National University), Masatoshi Kudo(Kindai University), В. В. Бредер(Russian Cancer Research Center NN Blokhin), Philippe Merle(Hôpital de la Croix-Rousse), Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), D. Li(Beckman Research Institute), Wendy Verret, Zhen Xu(Roche (China)), Sairy Hernandez(La Roche College), J. Liu(Roche (China)), Chen Huang(Roche (China)), S. Mulla(Roche (Canada)), Ho Yeong Lim(Sungkyunkwan University), Richard S. Finn(UCLA Jonsson Comprehensive Cancer Center)
Cited by 196
Abstract
Related Papers
No related papers found
Powered by citation graph analysis